10 Stocks Under $10 with High Potential
On January 17, Ryan Detrick from Carson Group appeared on a CNBC Television interview to discuss the current market situation and future outlook.
Mannkind Corp (MNKD)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Rubric Capital Management David Rosen | 11,414,671 | $61,296,783 | 0.69% | |
| 2. | Nitorum Capital Seth Rosen | 6,561,465 | $35,235,067 | -7% | 6.19% |
| 3. | VenBio Select Advisor Kurt Von Emster | 4,468,877 | $23,997,869 | -24% | 0.31% |
| 4. | Eversept Partners Kamran Moghtaderi | 2,042,727 | $10,969,444 | +193% | 0.76% |
| 5. | Two Sigma Advisors John Overdeck And David Siegel | 1,831,327 | $9,834,226 | -46% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.93 | 791 | $2,317.63 | 728,997 | 2022-07-31 | Filing | |
| $2.93 | 3,147 | $9,220.71 | 2,084,486 | 2022-07-31 | Filing | |
| $2.93 | 4,581 | $13,422.33 | 830,650 | 2022-07-31 | Filing | |
| $2.93 | 5,000 | $14,650.00 | 781,690 | 2022-07-31 | Filing | |
| $2.71 | 36,900 | $99,999.00 | 576,690 | 2022-02-28 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.33 | 47,006 | $297,547.98 | 985,007 | 2026-01-08 | Filing | |
| $6.01 | 65,804 | $395,482.04 | 2,504,792 | 2025-12-17 | Filing | |
| $6.00 | 21,310 | $127,860.00 | 2,504,792 | 2025-12-16 | Filing | |
| $6.00 | 20,806 | $124,836.00 | 2,504,792 | 2025-12-12 | Filing | |
| $5.57 | 107,920 | $601,114.40 | 2,504,792 | 2025-12-02 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 17,880,873 | $101,384,549 | 0% | |
| 2. | 5,103,097 | $28,934,560 | 0% | |
| 3. | 2,963,175 | $16,801,206 | 4.11% | |
| 4. | 2,958,944 | $16,777,214 | 1.91% | |
| 5. | 974,700 | $5,526,549 | 0.92% |
News See All
MannKind Corporation (MNKD) Secures FDA Approval for FUROSCIX Pediatric Use, Expanding Reach In Heart, Kidney Disease Care
MannKind Corporation (NASDAQ:MNKD) is one of the best NASDAQ stocks to buy in 2026.
12 Best NASDAQ Stocks to Buy in 2026
On December 30, Victoria Fernandez, Crossmark Chief Market Strategist, joined 'Closing Bell' on CNBC to discuss investment strategies for the technology sector as we head into 2026.
MannKind Corporation (NASDAQ:MNKD) Q3 2025 Earnings Call Transcript
Operator: Good morning, and welcome to the MannKind Corporation Third Quarter 2025 Financial Results Earnings Call.
H.C. Wainwright Reiterates a Buy Rating on MannKind Corporation (MNKD)
MannKind Corporation (NASDAQ:MNKD) is one of the best long-term penny stocks to buy right now. On August 25, H.C.
14 Best Long-Term Penny Stocks to Buy Right Now
On August 29, Ed Yardeni, President of Yardeni Research, appeared on CNBC’s ‘Closing Bell’ to talk about the latest news impacting markets, the possible factors that might inspire the next market...
MannKind Corporation (MNKD) Seeks FDA Pediatric Approval for Afrezza
MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company developing inhaled therapeutic products for endocrine and orphan lung diseases.
Leerink Partners Reiterates a Buy Rating on MannKind Corporation (MNKD), Keeps the PT at $7
MannKind Corporation (NASDAQ:MNKD) is one of the top strong buy stocks under $5 to buy now.
15 Strong Buy Stocks Under $5 to Buy Now
On August 22, Tom Lee, head of research and chief investment officer of Fundstrat Capital, appeared on CNBC’s ‘Squawk on the Street’ to talk about what he thinks about Fed Chair Powell’s speech...
10 Best Biotech Stocks to Buy Under $10
The head biotech analyst at Goldman Sachs, Salveen Richter, appeared on CNBC's "Squawk Box" on July 25 to discuss various topics, including the current status of the biotech industry and what to expect...
Hedge Fund Resource Center Billionaire Hedge Funds
